Clinical characteristics.

Leber congenital amaurosis (LCA), a severe dystrophy of the retina, typically becomes evident in the first year of life. Visual function is usually poor and often accompanied by nystagmus, sluggish or near-absent pupillary responses, photophobia, high hyperopia, and keratoconus. Visual acuity is rarely better than 20/400. A characteristic finding is Franceschetti's oculo-digital sign, comprising eye poking, pressing, and rubbing. The appearance of the fundus is extremely variable. While the retina may initially appear normal, a pigmentary retinopathy reminiscent of retinitis pigmentosa is frequently observed later in childhood. The electroretinogram (ERG) is characteristically "nondetectable" or severely subnormal.

Diagnosis/testing.

The diagnosis of LCA is established by clinical findings. Pathogenic variants in 17 genes are known to cause LCA: GUCY2D (locus name: LCA1), RPE65 (LCA2), SPATA7 (LCA3), AIPL1 (LCA4), LCA5 (LCA5), RPGRIP1 (LCA6), CRX (LCA7), CRB1 (LCA8), NMNAT1 (LCA9), CEP290 (LCA10), IMPDH1 (LCA11), RD3 (LCA12), RDH12 (LCA13), LRAT (LCA14), TULP1 (LCA15), KCNJ13 (LCA16), and IQCB1. Together, pathogenic variants in these genes are estimated to account for more than half of all LCA diagnoses. At least one other disease locus for LCA has been reported, but the gene is not known.

Management.

Treatment of manifestations: Treatment is supportive. Children and their parents should be referred to programs for the visually impaired child within their state or locality. Affected individuals benefit from correction of refractive error, use of low-vision aids when possible, and optimal access to educational and work-related opportunities.

Prevention of secondary complications: When possible children should be discouraged from repeatedly poking and pressing on their eyes.

Surveillance: Periodic ophthalmic evaluation for assessment of vision, trials of correction for refractive error, and, in those with residual vision, assessment of the presence of amblyopia, glaucoma, or cataract.

Genetic counseling.

Most often LCA is inherited in an autosomal recessive manner. At conception, each sib of an individual with recessively inherited LCA has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk family members is possible if the pathogenic variants in the family are known. Prenatal testing for pregnancies at increased risk is possible through laboratories offering either testing for the gene of interest or custom testing. Rarely, LCA is inherited in an autosomal dominant manner as a result of a pathogenic variant in CRX; the possibility of autosomal dominant inheritance resulting from a de novo CRX pathogenic variant should be considered in individuals with LCA and no family history of the disease.

Clinical Diagnosis

The form of congenital or early-infantile blindness known as Leber congenital amaurosis (LCA) was first defined by Theodor Leber in 1869 and 1871 on the basis of clinical findings [Leber 1869, Leber 1871]. While no universally agreed-upon diagnostic criteria are available, the following features are highly suggestive:

• Blindness or severe visual impairment presenting in infancy, frequently before age six months. Individuals with LCA usually do not achieve visual acuity better than 20/400 [Cremers et al 2002].
• Extinguished or severely reduced scotopic and photopic electroretinogram (ERG). Normal ERG responses rule out a diagnosis of LCA. Visual evoked responses are variable.
• The oculo-digital sign, characterized by poking, rubbing, and/or pressing of the eyes [Fazzi et al 2003]. The oculo-digital sign has been claimed to be virtually pathognomonic for LCA; however, it can also be seen in other syndromic forms of severe vision impairment.
• Family history typically consistent with autosomal recessive inheritance

Individuals with LCA also frequently exhibit the following:

• Sluggish or near-absent pupillary reactions reflecting the severe retinal dysfunction
• Nystagmus that is pendular or roving and present in all positions of gaze
• High hyperopia (>5 diopters), which is thought to result from impaired emmetropization (the ability of the eye to accommodate to visual stimuli) as a consequence of early-onset visual impairment
• Photophobia
• Keratoconus, a noninflammatory, self-limiting axial ectasia of the central cornea. Keratoconus can significantly interfere with vision in normal individuals but usually does not become a vision-limiting factor in LCA.

Retinal findings. No retinal lesion is diagnostic of LCA or specific for certain genetic subtypes. Although fundus abnormalities are frequently present later in life, infants with LCA typically show either a normal fundus appearance or only subtle retinal pigment epithelial (RPE) granularity, retinal vessel attenuation and, uncommonly, various stages of macular atrophy.

Of note, three more specific retinal phenotypes can be observed:

• Preserved para-arteriolar retinal pigment epithelium (PPRPE) in individuals with CRB1 pathogenic variants
• "Translucent RPE," white dots, and a peculiar star-shaped maculopathy in individuals with RPE65 pathogenic variants
• A progressive macular atrophic lesion presenting in infancy or later in some individuals. Because of its sharply defined borders, this lesion has been at times called a “macular coloboma.” While it has been reported to occur with pathogenic variants in AIPL1 and CRB1, the correlation of this LCA phenotype is most prominent with pathogenic variants in NMNAT1 [Chiang et al 2012, Falk et al 2012, Koenekoop et al 2012, Perrault et al 2012].

Molecular Genetic Testing

Genes. Pathogenic variants in seventeen genes are known to cause Leber congenital amaurosis (LCA) (Table 1).

Testing Strategy

To establish the diagnosis in a proband. Hanein et al [2004] proposed a clinical flowchart using the presence or absence of photophobia, night blindness, hyperopia, macular/peripheral retinal abnormalities, and measurable acuity to help direct the order of genes selected for molecular studies.

• Multigene testing. Consider using a multigene Leber congenital amaurosis panel that includes many genes associated with LCA. These panels vary by methods used and genes included; thus, the ability of a panel to detect a causative variant or variants in any given individual also varies. For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic tests can be found here.

Carrier testing for autosomal recessive LCA for relatives at-risk requires prior identification of the pathogenic variants in the family. Note: Carriers are heterozygotes for these autosomal recessive disorders and are not at risk of developing the disorder.

Prenatal diagnosis and preimplantation genetic testing for at-risk pregnancies require prior identification of the pathogenic variant(s) in the family.

Clinical Description

Leber congenital amaurosis (LCA) has retinal, ocular, and extraocular features and occasionally, systemic associations [Fazzi et al 2003].

Retina. The retina may appear normal initially; later, a variety of abnormalities may develop either in isolation or combination:

• "Macular coloboma"; not a true coloboma, but reflecting discrete chorioretinal degeneration and atrophy centered about the fovea
• "Bone-spicule" intraretinal pigment migration
• Widespread subretinal flecks resembling retinitis punctata albescens
• "Marbled" fundus
• Discrete pigmented nummular lesions at the level of the retinal pigment epithelium (RPE)
• Optic disc abnormalities: swelling, drusen formation, and peripapillary neovascularization

Oculo-digital sign. The characteristic extraocular sign in LCA is Franceschetti's oculo-digital sign, comprising three components: eye poking, pressing, and rubbing. It is not known why this behavior occurs. The major sequelum is enophthalmos, a physical defect in which the eye recedes into the orbit, presumably from atrophy of orbital fat. Keratoconus has been said to result from the repetitive trauma to the cornea, but others have suggested that this may be a feature of LCA itself.

Intellectual disability. Rarely, LCA is seen in association with neurodevelopmental delay, intellectual disability, and oculomotor apraxia-type behavior. However, many if not most of the historical reports date to earlier studies in which systemic phenocopies of LCA (see Differential Diagnosis) were not considered or ruled out. Still, some studies suggest that as many as 20% of children with LCA without associated anomalies develop intellectual disability [Schuil et al 1998]. Whether these individuals represent undiagnosed systemic disorders or a genetic subtype of LCA is unknown.

Prior to the identification of CEP290, none of the molecularly defined types of LCA was shown to be associated with intellectual disability or neurodevelopmental degeneration. Perrault et al [2007] reported a subset of individuals (15%) with CEP290-related LCA who have intellectual disability or autistic features, but no other extraretinal manifestations. Two of the six individuals in the study with intellectual disability or autism were later reclassified as having Joubert syndrome based on the presence of the “molar tooth” sign on MRI. In others, the MRI was apparently normal.

Visual impairment. Profound visual impairment is usually present from birth. One third of individuals with LCA have no perception of light. The visual impairment is generally stable or very slowly progressive. Occasionally in the early stages, a mild degree of visual improvement is observed. This improvement has been attributed to development of the central visual pathways rather than retinal maturation. Sustained improvements in acuity, visual field, and electrophysiologic measurements have been reported in one individual with a c.529delG pathogenic variant in CRX [Koenekoop et al 2002b]. Loss of visual acuity typically results from keratoconus, cataract, or evolving macular lesions.

Carriers. Carriers (heterozygotes) are usually asymptomatic; however, some heterozygotes for GUCY2D pathogenic variants have been shown to have mild cone dysfunction measured by decreased cone responses on electroretinogram [Koenekoop et al 2002a]. However, this is not associated with any findings on ophthalmologic examination and does not appear to interfere with vision.

Genotype-Phenotype Correlations

A number of genotype-phenotype correlations appear to have emerged.

GUCY2D (LCA1). Pathogenic variants in GUCY2D, which encodes retinal guanylyl cyclase 1 (RetGC), have been associated with a congenital severe cone-rod dystrophy characterized by photophobia, high hyperopia, and poor but stable vision with no visual improvement [Perrault et al 1999, Lorenz et al 2000, Hanein et al 2004]. However, Perrault et al [2005] described a man with early-onset RP resulting from the homozygous 4-bp pathogenic variant p.[His1079GlnfsTer54]+[His1079GlnfsTer54] in GUCY2D. The man has night blindness, peripheral vision loss, and preservation of central vision typical of RP. Unlike most null variants described in GUCY2D to date, p.His1079GlnfsTer54 is predicted to result in an elongation of the protein and residual protein function [Perrault et al 2005].

RPE65 (LCA2). Pathogenic variants in RPE65 have been associated with night blindness, some transient improvement in vision, and eventual progressive visual loss [Perrault et al 1999, Dharmaraj et al 2000b]. Lorenz found that four individuals with LCA and RPE65 pathogenic variants had measurable visual acuity at age six to ten years, despite severe visual impairment from infancy and nystagmus in three of the four [Lorenz et al 2000]. Photophobia was not a feature and all individuals had preservation of measurable peripheral vision. Rod ERG responses were undetectable, whereas cone ERG responses were detectable in early childhood.

Paunescu et al [2005] presented detailed follow-up data on three adult sibs with LCA suggesting that photophobia and progressive visual loss occur with age. Using a genotyping microarray, Zernant et al [2005] found that only five of 69 individuals with LCA (7%) with detectable pathogenic variants had an RPE65 genotype. This detection rate, lower than previous studies would predict, suggests that allelic variation in RPE65 may be more highly associated with early-onset severe retinal dystrophy than with classic LCA [Authors, personal observation].

Individuals with pathogenic variants in RPE65 may also demonstrate "translucent RPE," white dots, and a peculiar star-shaped maculopathy [Weleber et al 2011].

AIPL1 (LCA4). Dharmaraj et al [2004] studied 303 individuals with LCA and found that 26 probands (8.5% of their cohort) harbored homozygous or heterozygous pathogenic variants in AIPL1. Fourteen (54%) of these 26 individuals had at least one allele with the p.Trp278Ter pathogenic variant. The authors described the phenotype of LCA in these individuals and compared them to those observed and reported with LCA from pathogenic variants in GUCY2D, RPE65, CRX, CRB1, and RPGRIP1. The phenotype of LCA in individuals with AIPL1 pathogenic variants was found to be relatively severe, with maculopathy and marked bone-spicule pigmentary retinopathy in most and keratoconus and cataract in a large subset. The authors conclude that the visual loss associated with mutation of AIPL1 is similar in severity to that observed with mutation of GUCY2D. Pennesi et al [2011] reported a unique electroretinogram phenotype characterized by slow insensitive scotopic responses (SISR), which if present on testing may suggest this genetic form of LCA.

LCA5 (LCA5). In the Old River Brethren family originally linked to LCA5, severe visual dysfunction, nystagmus, the oculodigital sign, and a normal fundus were noted in all affected individuals in infancy. High hyperopia and attenuated retinal vasculature developed over time, and ERG recordings were severely reduced [Dharmaraj et al 2000a]. Den Hollander et al [2007] defined pathogenic variants within LCA5 in multiple unrelated families, all of whom presented with a similar, severe congenital retinal dystrophy. One of the families, reported earlier by Mohamed et al [2003], developed macular abnormalities including macular coloboma and atrophy. Renal, neurologic, cognitive, and hepatic functions have been normal across all affected families. Individuals with LCA5 have been shown to have spared photoreceptors, mostly in the macular region, that are adjacent to disorganized retina [Jacobson et al 2009].

RPGRIP1 (LCA6). Hanein et al [2004] described the following features as characteristic of RPGRIP1 pathogenic variants: early photophobia, hypermetropia less than +7 diopters, and visual acuity in the range of 20/400 to count fingers (CF). In follow up of individuals with LCA, Galvin et al [2005] found that visual acuity in children with pathogenic variants in RPGRIP frequently progresses to light perception (LP) or no light perception (NLP) within the first decade of life.

CRX (LCA7). Pathogenic variants in CRX have also been reported to be associated with stable vision [Dharmaraj et al 2000b] or even some modest improvement [Koenekoop et al 2002b]. Single or double base-pair deletions of the gene account for only the dominant forms of LCA, as a result of either an inherited dominant pathogenic variant or a de novo mutational event [Sohocki et al 1998, Rivolta et al 2001, Tzekov et al 2001, Perrault et al 2003].

CRB1 (LCA8). Night blindness is a constant feature of LCA resulting from CRB1 pathogenic variants. Jacobson et al [2003] found thick unlaminated retinas by optical coherence tomography (OCT) in individuals with LCA and CRB1 defects. Although some individuals with RP resulting from CRB1 pathogenic variants have the fundus appearance of preserved para-arteriolar RPE (PPRPE), no individuals with LCA resulting from CRB1 pathogenic variants have yet been reported to have PPRPE [den Hollander et al 2001].

CEP290 (LCA10). Two independent series of individuals with CEP290 pathogenic variants [den Hollander et al 2006, Perrault et al 2007] confirm a “typical” ophthalmologic LCA phenotype consisting of a severe infantile-onset cone-rod dystrophy with high hyperopia and severe ERG abnormalities. In addition, each series described a single individual with a reticular pigment epithelium in the peripheral retina with multiple white dots. This specific phenotype has not been reported with the other LCA-associated genes.

Extraretinal findings were described in a subset of individuals in Perrault’s study, and primarily included hypotonia and ataxia or intellectual disability and autistic behaviors. In fact, six of 40 families segregating CEP290 pathogenic variants were reported to have at least one affected individual with intellectual disability or autism. Two of those individuals were later reclassified as having Joubert syndrome on the basis of the classic "molar tooth" sign on MRI. Interestingly, a high degree of intrafamilial variability was observed with respect to the presence or absence of intellectual disability, leading the authors to suggest the possibility of a third allele or modifier gene in the development of cognitive disability in this subtype of LCA.

IMPDH1 (LCA11). Bowne et al [2006] described heterozygous, apparently de novo IMPDH1 pathogenic variants in two unrelated individuals with a diagnosis of LCA. IMPDH1 is a gene previously known to be associated with autosomal dominant retinitis pigmentosa. The clinical description of one of the individuals reported by Bowne et al [2006] fits the classic LCA phenotype; the other appears to have an early-onset retinal dystrophy better fitting the diagnosis of SECORD (see Differential Diagnosis). Additional studies must be undertaken to assess the prevalence of IMPDH1 pathogenic variants in the LCA population.

RDH12 (LCA13). In a further study of the individuals studied by Hanein et al [2004], Perrault et al [2004] identified 11 distinct pathogenic variants of RDH12 in 8/44 individuals with LCA characterized by congenital severe progressive rod-cone dystrophy. All eight with RDH12 pathogenic variants had a clinical course similar to that of individuals with RPE65 pathogenic variants: mild or absent hyperopia, transient improvement of visual acuity, and eventual macular atrophy with severe disease progression. Loss of visual acuity, however, occurred at an earlier age in those with RDH12 pathogenic variants than in those with RPE65 pathogenic variants. No RDH12 pathogenic variants were observed in persons with LCA presenting with the congenital stationary cone-rod dystrophy form of the disease.

IQCB1. Individuals with pathogenic variants in IQCB1 often have greater loss of rod function than loss of cone function. All newly diagnosed individuals with LCA should have testing for pathogenic variants in this gene and, if found, should undergo careful monitoring of renal function.

Keratoconus has been reported to occur in individuals with specific pathogenic variants in the CRB1 and AIPL1 genes [Hameed et al 2000].

Photophobia and night blindness. Hanein et al [2004] performed molecular screening on 179 unrelated individuals with LCA and reported the genotype-phenotype correlations on 85 who were found to harbor pathogenic variants on one or both alleles in one of seven LCA-associated genes. Frequencies of mutation in each gene were as follows:

• GUCY2D. 21.2% (38/179 families)
• CRB1. 10% (18/179)
• RPE65. 6.1% (11/179)
• RPGRIP1. 4.5% (8/179)
• AIPL1. 3.4% (6/179)
• TULP1. 1.7% (3/179)
• CRX. 0.6% (1/179)

The authors found that the presence of photophobia or night blindness at ages one and two years distinguished two groups:

• Those with photophobia constituted a cone-rod dystrophy class and were found to have pathogenic variants of GUCY2D, RPGRIP1, and AIPL1.
• Those with night blindness constituted a rod-cone dystrophy class and were found to have pathogenic variants of CRB1, RPE65, TULP1, and CRX.

Prevalence

The birth prevalence of LCA is two to three per 100,000 births. The condition is the most common cause of inherited blindness in childhood and constitutes more than 5% of all retinal dystrophies. LCA accounts for the cause of blindness in more than 20% of children attending schools for the blind.

LCA appears to be more prevalent when consanguinity is common [Sitorus et al 2003].

Evaluations Following Initial Diagnosis

To establish the extent of disease in an individual diagnosed with Leber congenital amaurosis (LCA), the following evaluations are recommended:

• Electroretinogram (ERG) to confirm the diagnosis and to assess retinal function
• Clinical genetic assessment to evaluate for the presence of systemic abnormalities
• Clinical genetics consultation

Treatment of Manifestations

Except for RPE65-related LCA (see Therapies Under Investigation), no substantial treatment or cure for LCA exists, and, thus, care is supportive. Parents should be referred to programs for the visually impaired child within their state or locality.

Affected individuals benefit from correction of refractive error, use of low-vision aids when possible, and optimal access to educational and work-related opportunities.

Prevention of Secondary Complications

Children should be discouraged from repeatedly poking and pressing on their eyes, although attempts to alter such behavior are not always successful.

Surveillance

Affected individuals should be periodically seen for assessment of vision, trials of correction for refractive error, and when residual vision is present, assessment of the presence of amblyopia, glaucoma, or cataract.

Rarely, vision appears to improve beyond expectations; in such cases, a repeat ERG is indicated.

Evaluation of Relatives at Risk

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

Therapies Under Investigation

In a naturally occurring Briard dog model of LCA resulting from mutation of RPE65, gene therapy utilizing AAV-mediated RPE65 was shown to restore visual function, an effect that has been documented to last for more than five years [Acland et al 2005]. More than 50 dogs have now been treated, with sustained success in 95% of treated eyes. The results of three simultaneous Phase I clinical treatment trials of AAV-mediated RPE65 gene therapy in humans were recently reported [Bainbridge et al 2008, Cideciyan et al 2008, Hauswirth et al 2008, Maguire et al 2008]. Initial results demonstrated safety, and showed slight improvement in vision in both bright and dim light.

Clinical and laboratory studies suggest that persons with CEP290-related LCA may also be good candidates for gene therapy. Cideciyan et al [2008] studied the retinal architecture of CEP290-mutant mice and humans. In the mouse retina, dramatic retinal remodeling was evident by age four to six weeks. Cross-sectional imaging of affected human retinas performed using optical coherence tomography (OCT) indicated preservation of foveal cones. The relative sparing of foveal cone cells, despite severe visual dysfunction, suggests an opportunity for cell rescue.

Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions.

Mode of Inheritance

Most often, Leber congenital amaurosis (LCA) is inherited in an autosomal recessive manner. Rarely, pathogenic variants in CRX causing LCA are inherited in an autosomal dominant manner.

Autosomal Recessive LCA – Risk to Family Members

Parents of a proband

• The parents of an affected child are obligate heterozygotes and therefore carry one mutated allele.
• Heterozygotes (carriers) are asymptomatic.

Sibs of a proband

• At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.
• Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3.
• Heterozygotes (carriers) are asymptomatic.

Offspring of a proband. The offspring of an individual with Leber congenital amaurosis are obligate heterozygotes (carriers) for a pathogenic variant.

Other family members of a proband. Sibs of the proband's parents are at a 50% risk of being carriers.

Autosomal Dominant LCA – Risk to Family Members

Parents of a proband

• Most children diagnosed as having autosomal dominant LCA have an affected parent.
• Occasionally a molecular diagnosis is made in the absence of family history. Such cases are the result of de novo pathogenic variants in CRX [Jacobson et al 1998, Sohocki et al 1998, Swaroop et al 1999, Rivolta et al 2001, Perrault et al 2003].

Sibs of a proband. The risk to sibs depends on the genetic status of the proband's parents:

• If one of the proband's parents is affected with LCA, the risk to sibs of inheriting the mutated allele is 50%.
• When neither parent of the proband is affected, the risk to sibs is negligible.

Offspring of a proband. Individuals with autosomal dominant LCA have a 50% chance of transmitting the mutated allele to each child.

Other family members of a proband. The risk to other family members depends on the status of the proband's parents: if a parent is affected, his or her family members are at risk.

Related Genetic Counseling Issues

Family planning

• The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal/preimplantation genetic testing is before pregnancy.
• It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.

DNA banking is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.

Prenatal Testing and Preimplantation Genetic Testing

Once the pathogenic variant(s) have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic testing for Leber congenital amaurosis are possible.

Literature Cited

• Acland GM, Aguirre GD, Bennett J, Aleman TS, Cideciyan AV, Bennicelli J, Dejneka NS, Pearce-Kelling SE, Maguire AM, Palczewski K, Hauswirth WW, Jacobson SG. Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther. 2005;12:1072–82. [PMC free article: PMC3647373] [PubMed: 16226919]
• Aldahmesh MA, Al-Owain M, Alqahtani F, Hazzaa S, Alkuraya FS. A null mutation in CABP4 causes Leber's congenital amaurosis-like phenotype. Mol Vis. 2010;16:207–12. [PMC free article: PMC2820108] [PubMed: 20157620]
• Araki T, Sasaki Y, Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science. 2004;305:1010–3. [PubMed: 15310905]
• Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, Viswanathan A, Holder GE, Stockman A, Tyler N, Petersen-Jones S, Bhattacharya SS, Thrasher AJ, Fitzke FW, Carter BJ, Rubin GS, Moore AT, Ali RR. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med. 2008;358:2231–9. [PubMed: 18441371]
• Bowne SJ, Sullivan LS, Mortimer SE, Hedstrom L, Zhu J, Spellicy CJ, Gire AI, Hughbanks-Wheaton D, Birch DG, Lewis RA, Heckenlively JR, Daiger SP. Spectrum and frequency of mutations in IMPDH1 associated with autosomal dominant retinitis pigmentosa and leber congenital amaurosis. Invest Ophthalmol Vis Sci. 2006;47:34–42. [PMC free article: PMC2581444] [PubMed: 16384941]
• Chiang PW, Wang J, Chen Y, Fu Q, Zhong J, Yi X, et al. Exome sequencing identifies NMNAT1 mutations as a cause of Leber congenital amaurosis. Nat Genet. 2012;44:972–4. [PubMed: 22842231]
• Chen S, Wang QL, Xu S, Liu I, Li LY, Wang Y, Zack DJ. Functional analysis of cone-rod homeobox (CRX) mutations associated with retinal dystrophy. Hum Mol Genet. 2002;11:873–84. [PubMed: 11971869]
• Cideciyan AV, Aleman TS, Boye SL, Schwartz SB, Kaushal S, Roman AJ, Pang JJ, Sumaroka A, Windsor EA, Wilson JM, Flotte TR, Fishman GA, Heon E, Stone EM, Byrne BJ, Jacobson SG, Hauswirth WW. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A. 2008;105:15112–7. [PMC free article: PMC2567501] [PubMed: 18809924]
• Cremers FP, van den Hurk JA, den Hollander AI. Molecular genetics of Leber congenital amaurosis. Hum Mol Genet. 2002;11:1169–76. [PubMed: 12015276]
• den Hollander AI, Heckenlively JR, van den Born LI, de Kok YJ, van der Velde-Visser SD, Kellner U, Jurklies B, van Schooneveld MJ, Blankenagel A, Rohrschneider K, Wissinger B, Cruysberg JR, Deutman AF, Brunner HG, Apfelstedt-Sylla E, Hoyng CB, Cremers FP. Leber congenital amaurosis and retinitis pigmentosa with Coats-like exudative vasculopathy are associated with mutations in the crumbs homologue 1 (CRB1) gene. Am J Hum Genet. 2001;69:198–203. [PMC free article: PMC1226034] [PubMed: 11389483]
• den Hollander AI, Koenekoop RK, Mohamed MD, Arts HH, Boldt K, Towns KV, Sedmak T, Beer M, Nagel-Wolfrum K, McKibbin M, Dharmaraj S, Lopez I, Ivings L, Williams GA, Springell K, Woods CG, Jafri H, Rashid Y, Strom TM, van der Zwaag B, Gosens I, Kersten FF, van Wijk E, Veltman JA, Zonneveld MN, van Beersum SE, Maumenee IH, Wolfrum U, Cheetham ME, Ueffing M, Cremers FP, Inglehearn CF, Roepman R. Mutations in LCA5, encoding the ciliary protein lebercilin, cause Leber congenital amaurosis. Nat Genet. 2007;39:889–95. [PubMed: 17546029]
• den Hollander AI, Koenekoop RK, Yzer S, Lopez I, Arends ML, Voesenek KE, Zonneveld MN, Strom TM, Meitinger T, Brunner HG, Hoyng CB, van den Born LI, Rohrschneider K, Cremers FP. Mutations in the CEP290 (NPHP6) gene are a frequent cause of Leber congenital amaurosis. Am J Hum Genet. 2006;79:556–61. [PMC free article: PMC1559533] [PubMed: 16909394]
• den Hollander AI, ten Brink JB, de Kok YJ, van Soest S, van den Born LI, van Driel MA, van de Pol DJ, Payne AM, Bhattacharya SS, Kellner U, Hoyng CB, Westerveld A, Brunner HG, Bleeker-Wagemakers EM, Deutman AF, Heckenlively JR, Cremers FP, Bergen AA. Mutations in a human homologue of Drosophila crumbs cause retinitis pigmentosa (RP12). Nat Genet. 1999;23:217–21. [PubMed: 10508521]
• Dharmaraj S, Leroy BP, Sohocki MM, Koenekoop RK, Perrault I, Anwar K, Khaliq S, Devi RS, Birch DG, De Pool E, Izquierdo N, Van Maldergem L, Ismail M, Payne AM, Holder GE, Bhattacharya SS, Bird AC, Kaplan J, Maumenee IH. The Phenotype of Leber Congenital Amaurosis in Patients With AIPL1 Mutations. Arch Ophthalmol. 2004;122:1029–37. [PubMed: 15249368]
• Dharmaraj S, Li Y, Robitaille JM, Silva E, Zhu D, Mitchell TN, Maltby LP, Baffoe-Bonnie AB, Maumenee IH. A novel locus for Leber congenital amaurosis maps to chromosome 6q. Am J Hum Genet. 2000a;66:319–26. [PMC free article: PMC1288337] [PubMed: 10631161]
• Dharmaraj SR, Silva ER, Pina AL, Li YY, Yang JM, Carter CR, Loyer MK, El-Hilali HK, Traboulsi EK, Sundin OK, Zhu DK, Koenekoop RK, Maumenee IH. Mutational analysis and clinical correlation in Leber congenital amaurosis. Ophthalmic Genet. 2000b;21:135–50. [PubMed: 11035546]
• Emanuelli M., Carnevali F., Saccucci F., Pierella F., Amici A., Raffaelli N., Magni G. Molecular cloning, chromosomal localization, tissue mRNA levels, bacterial expression, and enzymatic properties of human NMN adenylyltransferase. J. Biol. Chem. 2001;276:406–12. [PubMed: 11027696]
• Falk MJ, Zhang Q, Nakamaru-Ogiso E, Kannabiran C, Fonseca-Kelly Z, Chakarova C, et al. NMNAT1 mutations cause Leber congenital amaurosis. Nat Genet. 2012;44:1040–5. [PMC free article: PMC3454532] [PubMed: 22842227]
• Fazzi E, Signorini SG, Scelsa B, Bova SM, Lanzi G. Leber's congenital amaurosis: an update. Eur J Paediatr Neurol. 2003;7:13–22. [PubMed: 12615170]
• Friedman JS, Chang B, Kannabiran C, Chakarova C, Singh HP, Jalali S, Hawes NL, Branham K, Othman M, Filippova E, Thompson DA, Webster AR, Andreasson S, Jacobson SG, Bhattacharya SS, Heckenlively JR, Swaroop A. Premature truncation of novel protein, RD#, exhibiting subnuclear localization is associated with retinal degeneration. Am J Hum Genet. 2006;79:1059–70. [PMC free article: PMC1698706] [PubMed: 17186464]
• Galvin JA, Fishman GA, Stone EM, Koenekoop RK. Evaluation of genotype-phenotype associations in leber congenital amaurosis. Retina. 2005;25:919–29. [PubMed: 16205573]
• Haeseleer F, Jang GF, Imanishi Y, Driessen CA, Matsumura M, Nelson PS, Palczewski K. Dual-substrate specificity short chain retinol dehydrogenases from the vertebrate retina. J Biol Chem. 2002;277:45537–46. [PMC free article: PMC1435693] [PubMed: 12226107]
• Hagstrom SA, Watson RF, Pauer GJ, Grossman GH. Tulp1 is involved in specific photoreceptor protein transport pathways. Adv Exp Med Biol. 2012;723:783–9. [PubMed: 22183407]
• Hameed A, Abid A, Aziz A, Ismail M, Mehdi SQ, Khaliq S. Evidence of RPGRIP1 gene mutations associated with recessive cone-rod dystrophy. J Med Genet. 2003;40:616–9. [PMC free article: PMC1735563] [PubMed: 12920076]
• Hameed A, Khaliq S, Ismail M, Anwar K, Ebenezer ND, Jordan T, Mehdi SQ, Payne AM, Bhattacharya SS. A novel locus for Leber congenital amaurosis (LCA4) with anterior keratoconus mapping to chromosome 17p13. Invest Ophthalmol Vis Sci. 2000;41:629–33. [PubMed: 10711674]
• Hanein S, Perrault I, Gerber S, Tanguy G, Barbet F, Ducroq D, Calvas P, Dollfus H, Hamel C, Lopponen T, Munier F, Santos L, Shalev S, Zafeiriou D, Dufier JL, Munnich A, Rozet JM, Kaplan J. Leber congenital amaurosis: comprehensive survey of the genetic heterogeneity, refinement of the clinical definition, and genotype-phenotype correlations as a strategy for molecular diagnosis. Hum Mutat. 2004;23:306–17. [PubMed: 15024725]
• Hauswirth WW, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB, Wang L, Conlon TJ, Boye SL, Flotte TR, Byrne BJ, Jacobson SG. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther. 2008;19:979–90. [PMC free article: PMC2940541] [PubMed: 18774912]
• Heegaard S, Rosenberg T, Preising M, Prause JU, Bek T. An unusual retinal vascular morphology in connection with a novel AIPL1 mutation in Leber's congenital amaurosis. Br J Ophthalmol. 2003;87:980–3. [PMC free article: PMC1771788] [PubMed: 12881340]
• Hildebrandt F, Zhou W. Nephronophthisis-associated ciliopathies. J Am Soc Nephrol. 2007;18:1855–71. [PubMed: 17513324]
• Jacobson SG, Aleman TS, Cideciyan AV, Sumaroka A, Schwartz SB, Windsor EAM, Swider M, Herrera W, Stone EM. Leber congenital amaurosis caused by Lebercilin (LCA5) mutation: retained photoreceptors adjacent to retinal disorganization. Mol Vis. 2009;15:1098–106. [PMC free article: PMC2690955] [PubMed: 19503738]
• Jacobson SG, Cideciyan AV, Aleman TS, Pianta MJ, Sumaroka A, Schwartz SB, Smilko EE, Milam AH, Sheffield VC, Stone EM. Crumbs homolog 1 (CRB1) mutations result in a thick human retina with abnormal lamination. Hum Mol Genet. 2003;12:1073–8. [PubMed: 12700176]
• Jacobson SG, Cideciyan AV, Huang Y, Hanna DB, Freund CL, Affatigato LM, Carr RE, Zack DJ, Stone EM, McInnes RR. Retinal degenerations with truncation mutations in the cone-rod homeobox (CRX) gene. Invest Ophthalmol Vis Sci. 1998;39:2417–26. [PubMed: 9804150]
• Janecke AR, Thompson DA, Utermann G, Becker C, Hubner CA, Schmid E, McHenry CL, Nair AR, Ruschendorf F, Heckenlively J, Wissinger B, Nurnberg P, Gal A. Mutations in RDH12 encoding a photoreceptor cell retinol dehydrogenase cause childhood-onset severe retinal dystrophy. Nat Genet. 2004;36:850–4. [PubMed: 15258582]
• Kanaya K, Sohocki MM, Kamitani T. Abolished interaction of NUB1 with mutant AIPL1 involved in Leber congenital amaurosis. Biochem Biophys Res Commun. 2004;317:768–73. [PubMed: 15081406]
• Koenekoop RK, Fishman GA, Iannaccone A, Ezzeldin H, Ciccarelli ML, Baldi A, Sunness JS, Lotery AJ, Jablonski MM, Pittler SJ, Maumenee I. Electroretinographic abnormalities in parents of patients with Leber congenital amaurosis who have heterozygous GUCY2D mutations. Arch Ophthalmol. 2002a;120:1325–30. [PubMed: 12365911]
• Koenekoop RK, Loyer M, Dembinska O, Beneish R. Visual improvement in Leber congenital amaurosis and the CRX genotype. Ophthalmic Genet. 2002b;23:49–59. [PubMed: 11910559]
• Koenekoop RK, Wang H, Majewski J, Wang X, Lopez I, Ren H, et al. Mutations in NMNAT1 cause Leber congenital amaurosis and identify a new disease pathway for retinal degeneration. Nat Genet. 2012;44:1035–9. [PMC free article: PMC3657614] [PubMed: 22842230]
• Leber T. Ueber retinitis pigmentosa und angeborene Amaurose. Graefes Arch Clin Exp Ophthalmol. 1869;15:1–25.
• Leber T. Ueber hereditare und congenitalangelegte Schnervenleiden. Graefes Arch Clin Exp Ophthalmol. 1871;17:249–91.
• Littink KW, van Genderen MM, Collin RW, Roosing S, de Brouwer AP, Riemslag FC, Venselaar H, Thiadens AA, Hoyng CB, Rohrschneider K, den Hollander AI, Cremers FP, van den Born LI. A novel homozygous nonsense mutation in CABP4 causes congenital cone-rod synaptic disorder. Invest Ophthalmol Vis Sci. [Research Support, Non-U.S. Gov't]. 2009;50:2344-50. [PubMed: 19074807]
• Lorenz B, Gyurus P, Preising M, Bremser D, Gu S, Andrassi M, Gerth C, Gal A. Early-onset severe rod-cone dystrophy in young children with RPE65 mutations. Invest Ophthalmol Vis Sci. 2000;41:2735–42. [PubMed: 10937591]
• Lorenz B, Poliakov E, Schambeck M, Friedburg C, Preising MN, Redmond TM. A comprehensive clinical and biochemical functional study of a novel RPE65 hypomorphic mutation. Invest Ophthalmol Vis Sci. 2008;49:5235–42. [PMC free article: PMC5015590] [PubMed: 18599565]
• Lotery AJ, Jacobson SG, Fishman GA, Weleber RG, Fulton AB, Namperumalsamy P, Heon E, Levin AV, Grover S, Rosenow JR, Kopp KK, Sheffield VC, Stone EM. Mutations in the CRB1 gene cause Leber congenital amaurosis. Arch Ophthalmol. 2001;119:415–20. [PubMed: 11231775]
• Lotery AJ, Namperumalsamy P, Jacobson SG, Weleber RG, Fishman GA, Musarella MA, Hoyt CS, Heon E, Levin A, Jan J, Lam B, Carr RE, Franklin A, Radha S, Andorf JL, Sheffield VC, Stone EM. Mutation analysis of 3 genes in patients with Leber congenital amaurosis. Arch Ophthalmol. 2000;118:538–43. [PubMed: 10766140]
• Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, Bennicelli J, Banfi S, Marshall KA, Testa F, Surace EM, Rossi S, Lyubarsky A, Arruda VR, Konkle B, Stone E, Sun J, Jacobs J, Dell'Osso L, Hertle R, Ma JX, Redmond TM, Zhu X, Hauck B, Zelenaia O, Shindler KS, Maguire MG, Wright JF, Volpe NJ, McDonnell JW, Auricchio A, High KA, Bennett J. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med. 2008;358:2240–8. [PMC free article: PMC2829748] [PubMed: 18441370]
• McBee JK, Palczewski K, Baehr W, Pepperberg DR. Confronting complexity: the interlink of phototransduction and retinoid metabolism in the vertebrate retina. Prog Retin Eye Res. 2001;20:469–529. [PubMed: 11390257]
• Milam AH, Barakat MR, Gupta N, Rose L, Aleman TS, Pianta MJ, Cideciyan AV, Sheffield VC, Stone EM, Jacobson SG. Clinicopathologic effects of mutant GUCY2D in Leber congenital amaurosis. Ophthalmology. 2003;110:549–58. [PubMed: 12623820]
• Mohamed MD, Topping NC, Jafri H, Raashed Y, McKibbin MA, Inglehearn CF. Progression of phenotype in Leber's congenital amaurosis with a mutation at the LCA5 locus. Br J Ophthalmol. 2003;87:473–5. [PMC free article: PMC1771622] [PubMed: 12642313]
• Morimura H, Fishman GA, Grover SA, Fulton AB, Berson EL, Dryja TP. Mutations in the RPE65 gene in patients with autosomal recessive retinitis pigmentosa or leber congenital amaurosis. Proc Natl Acad Sci U S A. 1998;95:3088–93. [PMC free article: PMC19699] [PubMed: 9501220]
• Otto EA, Helou J, Allen SJ, O'Toole JF, Wise EL, Ashraf S, Attanasio M, Zhou W, Wolf MT, Hildebrandt F. Mutation analysis in nephronophthisis using a combined approach of homozygosity mapping, CEL I endonuclease cleavage, and direct sequencing. Hum Mutat. 2008;29:418–26. [PubMed: 18076122]
• Paunescu K, Wabbels B, Preising MN, Lorenz B. Longitudinal and cross-sectional study of patients with early-onset severe retinal dystrophy associated with RPE65 mutations. Graefes Arch Clin Exp Ophthalmol. 2005;243:417–26. [PubMed: 15565294]
• Pennesi ME, Stover NB, Stone EM, Chiang PW, Weleber RG. Residual electroretinograms in young Leber congenital amaurosis patients with mutations of AIPL1. Invest Ophthalmol Vis Sci. 2011;2011(52):8166–73. [PMC free article: PMC3208025] [PubMed: 21900377]
• Perrault I, Delphin N, Hanein S, Gerber S, Dufier JL, Roche O, Defoort-Dhellemmes S, Dollfus H, Fazzi E, Munnich A, Kaplan J, Rozet JM. Spectrum of NPHP6/CEP290 mutations in Leber congenital amaurosis and delineation of the associated phenotype. Hum Mutat. 2007;28:416. [PubMed: 17345604]
• Perrault I, Hanein S, Gerber S, Barbet F, Ducroq D, Dollfus H, Hamel C, Dufier JL, Munnich A, Kaplan J, Rozet JM. Retinal dehydrogenase 12 (RDH12) mutations in leber congenital amaurosis. Am J Hum Genet. 2004;75:639–46. [PMC free article: PMC1182050] [PubMed: 15322982]
• Perrault I, Hanein S, Gerber S, Barbet F, Dufier JL, Munnich A, Rozet JM, Kaplan J. Evidence of autosomal dominant Leber congenital amaurosis (LCA) underlain by a CRX heterozygous null allele. J Med Genet. 2003;40:e90. [PMC free article: PMC1735514] [PubMed: 12843339]
• Perrault I, Hanein S, Gerber S, Lebail B, Vlajnik P, Barbet F, Ducroq D, Dufier JL, Munnich A, Kaplan J, Rozet JM. A novel mutation in the GUCY2D gene responsible for an early onset severe RP different from the usual GUCY2D-LCA phenotype. Hum Mutat. 2005;25:222. [PubMed: 15643614]
• Perrault I, Hanein S, Zanlonghi X, Serre V, Nicouleau M, Defoort-Delhemmes S, et al. Mutations in NMNAT1 cause Leber congenital amaurosis with early-onset severe macular and optic atrophy. Nat Genet. 2012;44:975–7. [PubMed: 22842229]
• Perrault I, Rozet JM, Ghazi I, Leowski C, Bonnemaison M, Gerber S, Ducroq D, Cabot A, Souied E, Dufier JL, Munnich A, Kaplan J. Different functional outcome of RetGC1 and RPE65 gene mutations in Leber congenital amaurosis. Am J Hum Genet. 1999;64:1225–8. [PMC free article: PMC1377849] [PubMed: 10090910]
• Porto FB, Perrault I, Hicks D, Rozet JM, Hanoteau N, Hanein S, Kaplan J, Sahel JA. Prenatal human ocular degeneration occurs in Leber's congenital amaurosis (LCA2). J Gene Med. 2002;4:390–6. [PubMed: 12124981]
• Redmond TM, Poliakov E, Yu S, Tsai JY, Lu Z, Gentleman S. Mutation of key residues of RPE65 abolishes its enzymatic role as isomerohydrolase in the visual cycle. Proc Natl Acad Sci U S A. 2005;102:13658–63. [PMC free article: PMC1224626] [PubMed: 16150724]
• Rivolta C, Berson EL, Dryja TP. Dominant Leber congenital amaurosis, cone-rod degeneration, and retinitis pigmentosa caused by mutant versions of the transcription factor CRX. Hum Mutat. 2001;18:488–98. [PubMed: 11748842]
• Rozet JM, Perrault I, Gerber S, Hanein S, Barbet F, Ducroq D, Souied E, Munnich A, Kaplan J. Complete abolition of the retinal-specific guanylyl cyclase (retGC-1) catalytic ability consistently leads to leber congenital amaurosis (LCA). Invest Ophthalmol Vis Sci. 2001;42:1190–2. [PubMed: 11328726]
• Salomon R, Saunier S, Niaudet P. Nephronophthisis. Pediatr Nephrol. 2009;24:2333–44. [PMC free article: PMC2770134] [PubMed: 18607645]
• Sayer JA, Otto EA, O'Toole JF, Nurnberg G, Kennedy MA, Becker C, Hennies HC, Helou J, Attanasio M, Fausett BV, Utsch B, Khanna H, Liu Y, Drummond I, Kawakami I, Kusakabe T, Tsuda M, Ma L, Lee H, Larson RG, Allen SJ, Wilkinson CJ, Nigg EA, Shou C, Lillo C, Williams DS, Hoppe B, Kemper MJ, Neuhaus T, Parisi MA, Glass IA, Petry M, Kispert A, Gloy J, Ganner A, Walz G, Zhu X, Goldman D, Nurnberg P, Swaroop A, Leroux MR, Hildebrandt F. The centrosomal protein nephrocystin-6 is mutated in Joubert syndrome and activates transcription factor ATF4. Nat Genet. 2006;38:674–81. [PubMed: 16682973]
• Schuil J, Meire FM, Delleman JW. Mental retardation in amaurosis congenita of Leber. Neuropediatrics. 1998;29:294–7. [PubMed: 10029347]
• Sergouniotis PI, Davidson AE, Mackay DS, Li Z, Yang X, Plagnol V, Moore AT, Webster AR. Recessive mutations in KCNJ13, encoding an inwardly rectifying potassium channel subunit, cause Leber congenital amaurosis. Am. J. Hum. Genet. 2011;89:183–90. [PMC free article: PMC3135807] [PubMed: 21763485]
• Sitorus R, Preising M, Lorenz B. Causes of blindness at the "Wiyata Guna" School for the Blind, Indonesia. Br J Ophthalmol. 2003;87:1065–8. [PMC free article: PMC1771829] [PubMed: 12928266]
• Sohocki MM, Bowne SJ, Sullivan LS, Blackshaw S, Cepko CL, Payne AM, Bhattacharya SS, Khaliq S, Qasim Mehdi S, Birch DG, Harrison WR, Elder FF, Heckenlively JR, Daiger SP. Mutations in a new photoreceptor-pineal gene on 17p cause Leber congenital amaurosis. Nat Genet. 2000;24:79–83. [PMC free article: PMC2581448] [PubMed: 10615133]
• Sohocki MM, Sullivan LS, Mintz-Hittner HA, Birch D, Heckenlively JR, Freund CL, McInnes RR, Daiger SP. A range of clinical phenotypes associated with mutations in CRX, a photoreceptor transcription-factor gene. Am J Hum Genet. 1998;63:1307–15. [PMC free article: PMC1377541] [PubMed: 9792858]
• Stone EM. Leber congenital amaurosis - a model for efficient genetic testing of heterogeneous disorders: LXIV Edward Jackson Memorial Lecture. Am J Ophthalmol. 2007 Dec;144:791–811. [PubMed: 17964524]
• Swaroop A, Wang QL, Wu W, Cook J, Coats C, Xu S, Chen S, Zack DJ, Sieving PA. Leber congenital amaurosis caused by a homozygous mutation (R90W) in the homeodomain of the retinal transcription factor CRX: direct evidence for the involvement of CRX in the development of photoreceptor function. Hum Mol Genet. 1999;8:299–305. [PubMed: 9931337]
• Thompson DA, Janecke AR, Lange J, Feathers KL, Hubner CA, McHenry CL, Stockton DW, Rammesmayer G, Lupski JR, Antinolo G, Ayuso C, Baiget M, Gouras P, Heckenlively JR, den Hollander A, Jacobson SG, Lewis RA, Sieving PA, Wissinger B, Yzer S, Zrenner E, Utermann G, Gal A. Retinal degeneration associated with RDH12 mutations results from decreased 11-cis retinal synthesis due to disruption of the visual cycle. Hum Mol Genet. 2005;14:3865–75. [PubMed: 16269441]
• Thompson DA, Li Y, McHenry CL, Carlson TJ, Ding X, Sieving PA, Apfelstedt-Sylla E, Gal A. Mutations in the gene encoding lecithin retinol acyltransferase are associated with early-onset severe retinal dystrophy. Nat Genet. 2001;28:123–4. [PubMed: 11381255]
• Tzekov RT, Liu Y, Sohocki MM, Zack DJ, Daiger SP, Heckenlively JR, Birch DG. Autosomal dominant retinal degeneration and bone loss in patients with a 12-bp deletion in the CRX gene. Invest Ophthalmol Vis Sci. 2001;42:1319–27. [PMC free article: PMC2581450] [PubMed: 11328746]
• van der Spuy J, Kim JH, Yu YS, Szel A, Luthert PJ, Clark BJ, Cheetham ME. The expression of the Leber congenital amaurosis protein AIPL1 coincides with rod and cone photoreceptor development. Invest Ophthalmol Vis Sci. 2003;44:5396–403. [PubMed: 14638743]
• Wang H, den Hollander AI, Moayedi Y, Abulimiti A, Li Y, Collin RWJ, Hoyng CB, Lopez I, Bray M, Lewis RA, Lupski JR, Mardon G, Koenekoop RK, Chen R. Mutations in SPATA7 cause Leber congenital amaurosis and juvenile retinitis pigmentosa. Am J Hum Genet. 2009;84:380–7. [PMC free article: PMC2668010] [PubMed: 19268277]
• Weleber RG. The dystrophic retina in multisystem disorders: the electroretinogram in neuronal ceroid lipofuscinoses. Eye. 1998;12:580–90. [PubMed: 9775220]
• Weleber RG, Gupta N, Trzupek KM, Wepner MS, Kurz DE, Milam AH. Electroretinographic and clinicopathologic correlations of retinal dysfunction in infantile neuronal ceroid lipofuscinosis (infantile Batten disease). Mol Genet Metab. 2004;83:128–37. [PubMed: 15464427]
• Weleber RG, Michaelides M, Trzupek KM, Stover NB, Stone EM. The phenotype of Severe Early Childhood Onset Retinal Dystrophy (SECORD) from mutation of RPE65 and differentiation from Leber congenital amaurosis. Invest Ophthalmol Vis Sci. 2011;52:292–302. [PubMed: 20811047]
• Zeitz C, Kloeckener-Gruissem B, Forster U, Kohl S, Magyar I, Wissinger B, Matyas G, Borruat FX, Schorderet DF, Zrenner E, Munier FL, Berger W. Mutations in CABP4, the gene encoding the Ca2+-binding protein 4, cause autosomal recessive night blindness. Am J Hum Genet. 2006;79:657–67. [PMC free article: PMC1592568] [PubMed: 16960802]
• Zernant J, Kulm M, Dharmaraj S, den Hollander AI, Perrault I, Preising MN, Lorenz B, Kaplan J, Cremers FP, Maumenee I, Koenekoop RK, Allikmets R. Genotyping microarray (disease chip) for Leber congenital amaurosis: detection of modifier alleles. Invest Ophthalmol Vis Sci. 2005;46:3052–9. [PubMed: 16123401]
• Zhao Y, Hong DH, Pawlyk B, Yue G, Adamian M, Grynberg M, Godzik A, Li T. The retinitis pigmentosa GTPase regulator (RPGR)- interacting protein: subserving RPGR function and participating in disk morphogenesis. Proc Natl Acad Sci U S A. 2003;100:3965–70. [PMC free article: PMC153031] [PubMed: 12651948]

Suggested Reading

• Koenekoop RK. RPGRIP1 is mutated in Leber congenital amaurosis: a mini-review. Ophthalmic Genet. 2005;26:175–9. [PubMed: 16352478]

Acknowledgments

Supported in part by Foundation Fighting Blindness, Research to Prevent Blindness, and the Grousbeck Family Foundation.

Revision History

• 24 May 2018 (ma) Retired chapter: covered in LCA/EOSRD Overview
• 2 May 2013 (me) Comprehensive update posted live
• 30 March 2010 (me) Comprehensive update posted live
• 12 October 2006 (me) Comprehensive update posted live
• 9 November 2005 (rw) Revision: RDH12 gene identified
• 7 July 2004 (me) Review posted live
• 30 December 2003 (rw, pf, kt) Original submission